Compare CVS Health Corp (CVS) vs Verizon Communications Inc (VZ) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Verizon (VZ) trades at $47.06, up 0.15% on the day, with a bullish technical signal and strong fundamentals including a P/E of 12.26 and a 6%+ dividend yield. Recent quarterly earnings have consistently beaten estimates, and cash flow from operations remains robust at $37.14 billion for 2025. The company is shifting focus to broadband growth and AI infrastructure, highlighted by a major dark fiber deal with Alphabet.

Outlook is positive with a consensus price target of $49.69, though competitive threats from SpaceX's Starlink and high debt levels pose risks. The stock offers value and income appeal, supported by analyst buy ratings and institutional accumulation, but investors must weigh growth initiatives against sector challenges.